nurture.bio develops Tellus, a platform that makes the epigenome readable, understandable, and designable for biological research. The system ingests massive datasets, surfaces meaningful biological signals, and provides guidance on next experimental steps, turning raw epigenetic data into actionable answers for researchers.
Funding
Funding not disclosed
Founders
Product
Problem
Epigenomic data is vast and complex, and researchers lack tools that can efficiently process, interpret, and act on it. Traditional bioinformatics pipelines struggle with terabyte-scale datasets (e.g., whole-genome bisulfite sequencing), and separating meaningful biological signal from noise is slow and difficult, hindering research progress and translation.
Solution
Tellus is a unified platform for making the epigenome actionable. It ingests terabytes of raw data natively, layers diverse datasets together, and allows researchers to explore information in real time. The system applies analytical methods to reduce noise and highlight significant biological patterns, and it helps users determine their next move for experimental design or validation, all within a single interface. By making the epigenome computable, Tellus enables researchers to move from raw data to an answer rather than getting stuck in processing and interpretation bottlenecks.
Target Audience
The platform targets researchers and biologists in academic, clinical, and pharmaceutical settings who work with high-volume epigenetic data and need tools to accelerate hypothesis testing and interpretation.
Features
- Native ingestion and real-time layering of terabyte-scale epigenomic datasets for comprehensive analysis
- A visualization interface for exploring large-scale data, demonstrated with public examples like the biological clock of the human brain
- Proprietary algorithms that filter noise and highlight relevant biological signals to accelerate discovery
- An integrated design workbench that guides users on subsequent experimental steps or follow-up analyses
- A cloud-based platform accessible via private beta for early researchers to test with their own proprietary data